(Q51579418)

7 April 2018

title

Effect of doxazosin on fibrinolysis in hypertensive patients with and without insulin resistance. (English)

1 reference

7 April 2018

1 reference

Jeng JR

1

1 reference

7 April 2018

Sheu WH

2

1 reference

7 April 2018

Jeng CY

3

1 reference

7 April 2018

Huang SH

4

1 reference

7 April 2018

Shieh SM

5

1 reference

7 April 2018

language of work or name

English

0 references

publication date

1 October 1996

1 reference

7 April 2018

published in

American Heart Journal

1 reference

7 April 2018

volume

132

1 reference

7 April 2018

issue

4

1 reference

7 April 2018

page(s)

783-789

1 reference

7 April 2018

Insulin resistance in essential hypertension

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2896%2990312-9

Elevated fibrinogen and plasminogen activator inhibitor (PAI-1) in hypertension are related to metabolic risk factors for cardiovascular disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2896%2990312-9

Decreased fibrinolytic activity and increased platelet function in hypertension. Possible influence of calcium antagonism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2896%2990312-9

Correlation between blood fibrinolytic activity, plasminogen activator inhibitor level, plasma insulin level, and relative body weight in normal and obese subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2896%2990312-9

Effect of doxazosin monotherapy on blood pressure and plasma lipids in patients with essential hypertension

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2896%2990312-9

Glucose, insulin, and lipid metabolism in doxazosin-treated patients with hypertension

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2896%2990312-9

Effects of doxazosin and atenolol on the fibrinolytic system in patients with hypertension and elevated serum cholesterol

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2896%2990312-9

Plasminogen activator release during venous stasis and exercise as determined by a new specific assay

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2896%2990312-9

Evidence for a rapid inhibitor to tissue plasminogen activator in plasma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2896%2990312-9

Effect of pravastatin treatment on glucose, insulin, and lipoprotein metabolism in patients with hypercholesterolemia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2896%2990312-9

Comparison of impedance to insulin-mediated glucose uptake in normal subjects and in subjects with latent diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2896%2990312-9

Effect of Antihypertensive Drugs on Insulin, Glucose, and Lipid Metabolism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2896%2990312-9

Regulation of endothelial tissue plasminogen activator and plasminogen activator inhibitor type 1 synthesis by diacylglycerol, phorbol ester, and thrombin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2896%2990312-9

Detection and partial characterization of an inhibitor of plasminogen activator in human platelets

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2896%2990312-9

Stimulation of plasminogen activator inhibitor in vivo by infusion of angiotensin II. Evidence of a potential interaction between the renin-angiotensin system and fibrinolytic function

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2896%2990312-9

10.1016/S0002-8703(96)90312-9

7 January 2021

Identifiers

DOI

1 reference

7 April 2018

1 reference

7 April 2018